GambiaTuberculosis profile
Population  2016 2 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.43 (0.28–0.6) 21 (14–30)
Mortality (HIV+TB only) 0.19 (0.14–0.24) 9.1 (6.6–12)
Incidence  (includes HIV+TB) 3.5 (2.7–4.5) 174 (132–221)
Incidence (HIV+TB only) 0.65 (0.49–0.84) 32 (24–41)
Incidence (MDR/RR-TB)** 0.11 (0.018–0.2) 5.4 (0.89–9.9)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.21 (0.16–0.27) 1.2 (0.87–1.5) 1.4 (1–1.7)
Males 0.22 (0.16–0.27) 1.9 (1.4–2.4) 2.2 (1.6–2.7)
Total 0.43 (0.32–0.54) 3.1 (2.3–3.9) 3.5 (2.7–4.5)
TB case notifications, 2016  
Total cases notified 2 498
Total new and relapse 2 498
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status 84%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 63%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 70% (55–93)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.18 (0.12–0.25)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 385 18%
          - on antiretroviral therapy 221 57%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  78
(19–140)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance 65% 74% 1 644
MDR/RR-TB cases tested for resistance to second-line drugs   2
Laboratory-confirmed cases MDR/RR-TB: 2, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 2, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2015 82% 2 463
Previously treated cases registered in 2015    
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 100% 2
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-01-18 Data: www.who.int/tb/data